Related Experiment Video

Updated: Sep 18, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.5K

NRG-BR008/HERO study: a Phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast

Lior Z Braunstein1, Melissa P Mitchell2, Hanna Bandos3

  • 1Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Future Oncology (London, England)
|June 27, 2025
PubMed
Abstract

Clinical Trial Registration:

NCT05705401 (ClinicalTrials.gov).

Keywords:
Breast-conservation therapyHER2-positive breast cancerHER2-targeted therapyadjuvant breast radiotherapybreast cancer treatmentoncological outcomesquality of life outcomes

More Related Videos

Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

18.3K
Voluntary Breath-hold Technique for Reducing Heart Dose in Left Breast Radiotherapy
11:38

Voluntary Breath-hold Technique for Reducing Heart Dose in Left Breast Radiotherapy

Published on: July 3, 2014

46.9K

Related Experiment Videos

Last Updated: Sep 18, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.5K
Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

18.3K
Voluntary Breath-hold Technique for Reducing Heart Dose in Left Breast Radiotherapy
11:38

Voluntary Breath-hold Technique for Reducing Heart Dose in Left Breast Radiotherapy

Published on: July 3, 2014

46.9K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K

Articles linked to this work by shared authors, journal, and citation graph.

Dosimetric and Mammographic Predictors of Breast Lymphedema After Breast-Conserving Therapy.

International journal of radiation oncology, biology, physics·2026

Evaluation of a Tumor-Informed Molecular Residual Disease Assay in Early Triple-Negative Breast Cancer Treated With Neoadjuvant Chemotherapy, With or Without Atezolizumab.

JCO precision oncology·2026

Closing the recapitulation gap in obesity-conditioned TNBC drug development.

npj drug discovery·2026

Atezolizumab in early triple-negative breast cancer: the randomized phase 3 NSABP B-59/GeparDouze trial.

Nature medicine·2026

Association of English language proficiency and breast cancer oncologic outcomes.

JNCI cancer spectrum·2026

Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2-Negative Breast Cancer: The I-SPY2 Randomized Clinical Trial.

JAMA oncology·2026

Post-ASCO 2026: resident-led highlights of the most clinically relevant studies in genitourinary oncology.

Future oncology (London, England)·2026

SUNRAY-02: a study of olomorasib combined with immunotherapy in stage II-III KRAS G12C-mutant non-small cell lung cancer after definitive therapy.

Future oncology (London, England)·2026

DUBHE-H-308 study protocol: rationale and adaptive design of a randomized, open-label, seamless phaseII/III trial of iparomlimab and tuvonralimab (QL1706)-based regimens versus sintilimab plus bevacizumab as first-line treatment for advanced hepatocellular carcinoma.

Future oncology (London, England)·2026

STELLAR-311: a randomized phase II/III study of zanzalintinib versus everolimus in advanced neuroendocrine tumors.

Future oncology (London, England)·2026

First-line management of unresectable hepatocellular carcinoma: clinical perspectives from the CheckMate 9DW study.

Future oncology (London, England)·2026

A patient's experience with follicular lymphoma from diagnosis to cure: the life-changing impact of CAR T-cell therapy.

Future oncology (London, England)·2026

Repeated remimazolam sedation for interstitial brachytherapy in cervical cancer: a randomized controlled trial.

Annals of medicine·2026

Incidence, Patterns, and Predictive Factors of Biochemical Failure Following Definitive Radiotherapy for Localized Prostate Cancer: A Retrospective Military Cohort Study.

Cureus·2026

Radiation-Induced Pneumonitis Following Stereotactic Body Radiation Therapy for Left Upper Lobe Squamous Cell Carcinoma.

Cureus·2026

PSMA-PET/CT-guided Intensification of Radiation Therapy for Prostate Cancer (PSMAgRT): 5-yr Analysis of a Phase 2 Randomized Controlled Trial.

European urology·2026

Volume-based quantitative assessment of respiratory-induced organ motion in lung cancers.

Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)·2026

Stopping too soon: Search termination and subsequent search misses in diagnostic radiography.

Radiography (London, England : 1995)·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us